These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 36749127

  • 1. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S.
    J Am Soc Nephrol; 2023 May 01; 34(5):920-934. PubMed ID: 36749127
    [Abstract] [Full Text] [Related]

  • 2. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP.
    JAMA; 2020 Apr 14; 323(14):1378-1387. PubMed ID: 32286644
    [Abstract] [Full Text] [Related]

  • 3. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
    Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, Hauser IA, Alshuth U, Kliem V.
    Transplantation; 2018 May 14; 102(5):876-882. PubMed ID: 29166336
    [Abstract] [Full Text] [Related]

  • 4. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 5. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA.
    JAMA; 2023 Jul 03; 330(1):33-42. PubMed ID: 37279999
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
    Liu AW, Jutivorakool K, Fisher CE, Rakita RM, Reyes JD, Bhattacharya RB, Jerome KR, Limaye AP.
    Transplantation; 2018 Apr 03; 102(4):632-639. PubMed ID: 29215460
    [Abstract] [Full Text] [Related]

  • 7. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
    Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V.
    Am J Transplant; 2008 Jan 03; 8(1):69-77. PubMed ID: 17973956
    [Abstract] [Full Text] [Related]

  • 8. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 10. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients.
    Shi Y, Lerner AH, Rogers R, Vieira K, Merhi B, Mecadon K, Osband AJ, Bayliss G, Gohh R, Morrissey P, Farmakiotis D.
    Prog Transplant; 2021 Dec 16; 31(4):368-376. PubMed ID: 34839729
    [Abstract] [Full Text] [Related]

  • 11. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
    Belga S, Hernandez C, Kabbani D, Cervera C.
    Transpl Infect Dis; 2024 Apr 16; 26(2):e14227. PubMed ID: 38180285
    [Abstract] [Full Text] [Related]

  • 12. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W.
    Ann Intern Med; 2015 Jan 06; 162(1):1-10. PubMed ID: 25560711
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
    Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC.
    Am J Transplant; 2006 Sep 06; 6(9):2134-43. PubMed ID: 16780548
    [Abstract] [Full Text] [Related]

  • 14. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J, Phonphok K, Spanuchart I, Duong T, Sievers TM, Lum E, Reed EF, Bunnapradist S.
    Transpl Infect Dis; 2021 Feb 06; 23(1):e13457. PubMed ID: 32892447
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M.
    Clin J Am Soc Nephrol; 2015 Feb 06; 10(2):294-304. PubMed ID: 25424991
    [Abstract] [Full Text] [Related]

  • 16. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.
    J Clin Virol; 2015 Oct 06; 71():73-5. PubMed ID: 26318605
    [Abstract] [Full Text] [Related]

  • 17. A Comparison of Different Valgancyclovir Formulations in the Universal 6-Month Prophylaxis Against CMV Infection in Renal Transplant Recipients: A Randomized Single-Centre Study.
    Basic-Jukic N, Furic-Cunko V, Hudolin T, Zimak Z, Kirincich J, Kastelan Z.
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2019 Dec 01; 40(3):47-55. PubMed ID: 32109215
    [Abstract] [Full Text] [Related]

  • 18. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial.
    Páez-Vega A, Gutiérrez-Gutiérrez B, Agüera ML, Facundo C, Redondo-Pachón D, Suñer M, López-Oliva MO, Yuste JR, Montejo M, Galeano-Álvarez C, Ruiz-San Millan JC, Los-Arcos I, Hernández D, Fernández-Ruiz M, Muñoz P, Valle-Arroyo J, Cano A, Rodríguez-Benot A, Crespo M, Rodelo-Haad C, Lobo-Acosta MA, Garrido-Gracia JC, Vidal E, Guirado L, Cantisán S, Torre-Cisneros J, TIMOVAL Study Group.
    Clin Infect Dis; 2022 Mar 09; 74(5):757-765. PubMed ID: 34228099
    [Abstract] [Full Text] [Related]

  • 19. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2008 Feb 09; 14(2):240-4. PubMed ID: 18236404
    [Abstract] [Full Text] [Related]

  • 20. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J.
    Liver Transpl; 2012 Sep 09; 18(9):1093-9. PubMed ID: 22532316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.